P2RX3

Across TCGA pan-cancer cohorts, P2RX3 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated P2RX3 data layer compared with 17 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher P2RX3 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated P2RX3 expression acts as an unfavorable survival marker.

LUSC, ESCA, and GBM are the cancer types where P2RX3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	DFS	Median	II,III,IV	0.105	0.720	<.001	33	view →
ESCA	OS	Median	II,III,IV	0.130	0.703	<.001	24	view →
GBM	DFS	Median	All	0.048	0.257	.001	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
HNSC	OS	Median	All	0.166	0.710	.003	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SARC	DFS	Median	All	0.024	0.591	<.001	3	view →
LUAD	OS	Median	All	0.294	0.673	.042	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

P2RX3–LUSC (DFS)

Open the LUSC breakdown →